DT-2216 is under clinical development by Dialectic Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success ...
Something went wrong. Try again, or contact support if the problem persists. Your details are incorrect, or aren't in our system yet. Please try again, or sign up if you're new here.
Some results have been hidden because they may be inaccessible to you